N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=114 CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
Geographic Atrophy
Primary: Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug — 0; 0; 0 subjects
N/A N=12 Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea
Primary: Change in Apnea-Hypopnea Index (AHI) — 15.7; 7.1; -8.7 events per hour — p=0.0093
Phase 3 N=353 Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Study Period 1: Change in DAS28-CRP Score From Baseline at Week 12 in Patients Treated With GP2017 and Patients Treated With Humira — -2.16; -2.18 scores on a scale
Phase 3 N=719 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) Per Investigators' Assessment Based on Local Radiology Review - Full Population — 14.95; 14.49 months — p=0.1166
N/A N=602 Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida
Cervical Cancer
Primary: Number of Participants Completing a Self-sampling Test — 272; 257 Participants
Phase 2 N=25 Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematopoietic Engraftment — 17.9 days
Phase 3 N=140 Metformin Therapy for Overweight Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c. — 9.0; 8.9; 0.2; 0.2 percentage
N/A N=750 Assessment of Chiropractic Treatment for Low Back Pain and Smoking Cessation in Military Active Duty Personnel.
Lower Back Pain
Primary: Numerical Rating Scale (NRS) for Prior Week — 4.27; 4.36; 4.73; 4.45 units on a scale
N/A N=226 Tying Devices as a Means of Increasing Exercise
Healthy
Primary: Average Weekly Gym Attendance From Baseline to Week 9 — 1.21; 1.42; 0.94 Average Weekly Gym Attendance
Phase 4 N=40 Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
Diabetic Macular Edema
Primary: A Change Between Two Time Points is Reported for Maximum Reading Speed — 161.94; 167.65 words per minute
N/A N=17 Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
Breast Cancer
Primary: Change in Insulin Receptor Substrate 1 (IRS-1) / Phosphoinositide 3-kinase (PI3K) / Serine-threonine Protein Kinase (AKT) Pathway Activation — 388; -10; 157; 135 % change
Phase 4 N=22 Targeting the Right Ventricle in Pulmonary Hypertension
Pulmonary Hypertension
Primary: Changes in Right Ventricular Ejection Fraction — 5.8; -4.7; 0.49 percentage
Phase 2 N=104 An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: The Percentage of Participant With Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Within 2 Days After Any Dose in…
Phase 2 N=245 A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ — 5.42 months